AnaptysBio, Inc.

ANAB

US0327241065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/02/2026 GMT			5-day change	1st Jan Change
49.73 ^USD	+3.82%		+4.89%	+2.58%

01-14	AnaptysBio, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 04:30 PM
01-09	AnaptysBio Moves to Dismiss GSK's Tesaro Lawsuit Over Jemperli Royalty Dispute	MT

AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty

Published on 01/09/2026 at 12:07 am GMT

Reuters

Latest news about AnaptysBio, Inc.

01-14	AnaptysBio, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 04:30 PM
01-09	AnaptysBio Moves to Dismiss GSK's Tesaro Lawsuit Over Jemperli Royalty Dispute	MT
01-09	UK Stocks-Factors to watch on January 9	RE
01-09	AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty	RE
01-08	AnaptysBio Files to Dismiss Tesaro's Claim it Breached Royalties Contract	DJ
01-08	Anaptys files motion to dismiss Tesaro's claim of anticipatory breach of contract in ongoing litigation	RE
01-08	Anaptysbio Insider Sold Shares Worth $415,102, According to a Recent SEC Filing	MT
01-08	Anaptysbio Insider Sold Shares Worth $439,200, According to a Recent SEC Filing	MT
01-07	UBS Upgrades AnaptysBio to Buy From Neutral, Adjusts Price Target to $70 From $20	MT
12-23	Anaptysbio Insider Sold Shares Worth $510,000, According to a Recent SEC Filing	MT
12-23	Anaptysbio Insider Sold Shares Worth $500,000, According to a Recent SEC Filing	MT
12-15	Vanda announces submission of biologics license application to the FDA for Imsidolimab for the treatment of generalized pustular psoriasis	RE
11-28	Sector Update: Health Care Stocks Decline Friday Afternoon	MT
11-28	Sector Update: Health Care	MT
11-28	AnaptysBio, GSK's Tesaro Unit Likely Settle Jemperli Dispute Before July, Wedbush Says	MT
11-26	AnaptysBio's complaint against Tesaro for breaching agreement was publicly filed on Nov 26 - SEC filing	RE
11-24	AnaptysBio Presents Opportunity Despite 'Near-Term Turbulence' Amid Legal Dispute with GSK, Wedbush Says	MT
11-21	Health Care Up as Traders Seek Out Evergreen Sector -- Health Care Roundup	DJ
11-21	European Equities Close Mixed in Friday Trading; Eurozone Composite PMI Continues to Expand	MT
11-21	FTSE 100 Ticks Up Amid UK Retail Sales, Borrowing Data	MT
11-21	Sector Update: Health Care Stocks Rise Pre-Bell Friday	MT
11-21	Rate Cut Hopes Lift US Equity Futures Pre-Bell	MT
11-21	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday on Reignited Rate Cut Hopes	MT
11-21	Top Premarket Decliners	MT
11-21	AnaptysBio shares tumble after legal fight with GSK over cancer drug license	RE

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

Employees

136

Sector

Biotechnology & Medical Research

Calendar

02-11 - Guggenheim Emerging Outlook Biotech Summit

More about the company